Brought to you by 
Eddingpharm licenses Asian rights to Syndax's cancer candidate entinostat
03 Feb 2023
Executive Summary
Chinese drug company Eddingpharm International Holdings Ltd. has licensed exclusive rights in some Asian countries (China, Hong Kong, Thailand, Macau, Taiwan, Malaysia, and Singapore) to develop, manufacture, and sell oncology biotech Syndax Pharmaceuticals Inc.'s late-stage cancer candidate entinostat.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eddingpharm licenses Asian rights to Syndax's cancer candidate entinostat
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice